Reply to letter to editor "Cancer patients should be considered as a high-risk priority target in the COVID-19 vaccination process".

Rajan, Shiv; Akhtar, Naseem; Kumar, Vijay; Gupta, Sameer; Chaturvedi, Arun; Sharma, Sonali

Rajan, Shiv; Akhtar, Naseem; Kumar, Vijay; Gupta, Sameer; Chaturvedi, Arun; Sharma, Sonali.

Afiliação

Rajan S; Department of Surgical Oncology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Akhtar N; Department of Surgical Oncology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Kumar V; Department of Surgical Oncology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Gupta S; Department of Surgical Oncology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Chaturvedi A; Department of Surgical Oncology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Sharma S; Department of Gynecology and Obstetrics, King George's Medical University, Lucknow, Uttar Pradesh, India.

J Surg Oncol ; 124(3): 455, 2021 09.

Article em En | MEDLINE | ID: mdl-33878211

Assuntos

COVID-19; Neoplasias; Vacinas contra COVID-19; Humanos; SARS-CoV-2; Vacinação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Surg Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Índia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google